Anthem Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Anthem Biopharma's estimated annual revenue is currently $8M per year.
- Anthem Biopharma's estimated revenue per employee is $100,500
Employee Data
- Anthem Biopharma has 80 Employees.
- Anthem Biopharma grew their employee count by 4% last year.
Anthem Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $56.6M | 563 | 21% | N/A | N/A |
#2 | $15.6M | 155 | 28% | N/A | N/A |
#3 | $17M | 169 | -11% | N/A | N/A |
#4 | $13.2M | 131 | 8% | N/A | N/A |
#5 | $19.6M | 195 | 10% | N/A | N/A |
#6 | $23.5M | 234 | 7% | N/A | N/A |
#7 | $5.3M | 53 | 0% | N/A | N/A |
#8 | $13M | 129 | -25% | N/A | N/A |
#9 | $20.5M | 204 | 11% | N/A | N/A |
#10 | $11.7M | 116 | 6% | N/A | N/A |
What Is Anthem Biopharma?
Anthem Biopharma offers a well-rounded approach to the discovery, development and marketing of high quality healthcare products. We work together in partnership with several global and Indian large pharmaceutical companies to deliver high end healthcare products & services. Anthem is committed to reducing therapeutic cost of chronic diseases like autoimmune disorders, metabolic disorders, neurological disorders and cancer.
keywords:N/A
N/A
Total Funding
80
Number of Employees
$8M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Anthem Biopharma News
Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges ... Anthem Inc (NYSE:ANTM) 3% HIGHER; posted Q1 EPS of $8.25,...
The program's partners this year were Anthem, Blue Shield of California, Chicago Pacific Founders, Evernorth (a Cigna company),...
AbbVie Inc., AmerisourceBergen Corp., Anthem Inc. and UnitedHealth Group ... With hedge fund exposure to biopharma near a five-year low,...
Other Companies in Bangalore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11M | 80 | -8% | N/A |
#2 | $5.8M | 80 | 5% | N/A |
#3 | N/A | 80 | 54% | N/A |
#4 | $6.5M | 80 | 13% | N/A |
#5 | $10M | 80 | 4% | N/A |